Companhia de Saneamento Básico do Estado de São Paulo - SABESP Key Executives
This section highlights Companhia de Saneamento Básico do Estado de São Paulo - SABESP's key executives, including their titles and compensation details.
Find Contacts at Companhia de Saneamento Básico do Estado de São Paulo - SABESP
(Showing 0 of )
Companhia de Saneamento Básico do Estado de São Paulo - SABESP Earnings
This section highlights Companhia de Saneamento Básico do Estado de São Paulo - SABESP's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q1 | 2023 | 2023-05-12 | N/A | N/A |
Companhia de Saneamento Básico do Estado de São Paulo SABESP provides water and sewage services to residential, commercial, industrial, and governmental customers. It provides water supply, sanitary sewage, urban rainwater management and drainage, urban cleaning, and solid waste management services, as well as related activities, including the planning, operation, maintenance, and commercialization of energy. As of December 31, 2021, the company provided water services through 9.8 million water connections to approximately 27.8 million people; sewage services through 8.4 million sewage connections to approximately 24.6 million people; and operated 88,904 kilometers of water pipes and water transmission lines, as well as 61,122 kilometers of sewer lines. It also offers water and/or sewage services to four other municipalities through special purpose companies. The company was founded in 1954 and is headquartered in São Paulo, Brazil.
$17.66
Stock Price
$12.07B
Market Cap
11.17K
Employees
São Paulo, SP
Location
Financial Statements
Access annual & quarterly financial statements for Companhia de Saneamento Básico do Estado de São Paulo - SABESP, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Revenue | $25.57B | $22.06B | $19.49B | $17.80B | $17.98B |
| Cost of Revenue | $16.05B | $14.35B | $12.80B | $11.18B | $10.14B |
| Gross Profit | $9.52B | $7.70B | $6.69B | $6.62B | $7.85B |
| Gross Profit Ratio | 37.23% | 34.93% | 34.30% | 37.18% | 43.63% |
| Research and Development Expenses | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $1.37B | $1.40B | $944.02M | $878.11M | $1.03B |
| Selling and Marketing Expenses | $984.06M | $911.97M | $825.88M | $751.29M | $803.40M |
| Selling General and Administrative Expenses | $2.35B | $2.31B | $1.77B | $1.63B | $1.83B |
| Other Expenses | $821.20M | $773.73M | $845.62M | $510.24M | $308.72M |
| Operating Expenses | $3.17B | $3.08B | $2.62B | $2.14B | $2.14B |
| Cost and Expenses | $19.23B | $17.44B | $15.42B | $13.32B | $12.28B |
| Interest Income | $629.86M | $195.27M | $145.87M | $162.58M | $150.05M |
| Interest Expense | $1.41B | $1.22B | $734.86M | $751.96M | $658.88M |
| Depreciation and Amortization | $2.79B | $2.45B | $2.25B | $2.04B | $1.78B |
| EBITDA | $8.96B | $8.06B | $6.28B | $4.16B | $7.30B |
| EBITDA Ratio | 35.02% | 29.83% | 30.57% | 34.94% | 40.03% |
| Operating Income | $6.35B | $4.62B | $4.10B | $4.49B | $5.71B |
| Operating Income Ratio | 24.82% | 20.95% | 21.02% | 25.24% | 31.76% |
| Total Other Income Expenses Net | $-1.59B | $-372.41M | $-927.42M | $-3.17B | $-1.03B |
| Income Before Tax | $4.75B | $4.27B | $3.17B | $1.33B | $4.68B |
| Income Before Tax Ratio | 18.59% | 19.37% | 16.26% | 7.45% | 26.01% |
| Income Tax Expense | $1.23B | $1.15B | $864.29M | $352.68M | $1.31B |
| Net Income | $3.52B | $3.12B | $2.31B | $973.32M | $3.37B |
| Net Income Ratio | 13.78% | 14.15% | 11.83% | 5.47% | 18.73% |
| EPS | $5.16 | $4.57 | $3.37 | $1.42 | $4.93 |
| EPS Diluted | $5.16 | $4.57 | $3.37 | $1.42 | $4.93 |
| Weighted Average Shares Outstanding | 683.51M | 683.51M | 683.51M | 683.51M | 683.51M |
| Weighted Average Shares Outstanding Diluted | 683.51M | 683.51M | 683.51M | 683.51M | 683.51M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15.00B | $6.75B | $6.56B | $7.27B | $6.45B | $6.15B | $5.70B | $5.93B | $5.99B | $5.27B | $4.87B | $5.06B | $5.15B | $4.60B | $4.68B | $4.88B | $4.44B | $4.43B | $4.04B | $4.70B |
| Cost of Revenue | $3.99B | $-1.47B | $4.03B | $4.30B | $3.94B | $4.21B | $3.65B | $3.94B | $3.77B | $3.53B | $3.12B | $3.36B | $3.32B | $3.06B | $3.05B | $3.00B | $2.94B | $2.82B | $2.42B | $2.86B |
| Gross Profit | $11.01B | $8.22B | $2.53B | $2.97B | $2.51B | $1.94B | $2.04B | $2.00B | $2.22B | $1.73B | $1.75B | $1.70B | $1.83B | $1.53B | $1.63B | $1.89B | $1.50B | $1.61B | $1.62B | $1.84B |
| Gross Profit Ratio | 73.41% | 121.80% | 38.60% | 40.90% | 38.90% | 31.60% | 35.90% | 33.70% | 37.10% | 32.90% | 36.00% | 33.60% | 35.50% | 33.30% | 34.80% | 38.65% | 33.71% | 36.40% | 40.08% | 39.17% |
| Research and Development Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $651.48M | $425.45M | $538.14M | $438.28M | $419.08M | $430.85M | $284.68M | $392.69M | $357.80M | $341.20M | $253.79M | $266.65M | $243.55M | $249.56M | $184.27M | $246.54M | $198.19M | $184.97M | $248.41M | $261.09M |
| Selling and Marketing Expenses | $198.55M | $112.89M | $210.09M | $236.09M | $237.07M | $285.24M | $225.66M | $528.09M | $137.50M | $233.53M | $196.59M | $-149.57M | $315.84M | $199.66M | $194.79M | $-166.42M | $269.54M | $191.52M | $181.97M | $213.09M |
| Selling General and Administrative Expenses | $850.04M | $663.27M | $864.90M | $735.24M | $656.16M | $716.09M | $510.34M | $920.79M | $495.31M | $574.73M | $450.38M | $117.08M | $559.39M | $449.22M | $379.06M | $80.13M | $467.74M | $376.49M | $430.38M | $474.18M |
| Other Expenses | $310.00M | $- | $-21.43M | $-26.68M | $-25.18M | $-25.27M | $148.17M | $6.22M | $211.08M | $250.58M | $175.13M | $722.55M | $46.62M | $188.22M | $153.38M | $501.72M | $45.18M | $47.50M | $190.51M | $204.84M |
| Operating Expenses | $1.16B | $663.27M | $886.34M | $761.92M | $806.79M | $883.03M | $658.51M | $927.00M | $706.38M | $825.31M | $625.51M | $839.63M | $606.01M | $637.43M | $532.44M | $581.84M | $512.92M | $423.99M | $620.88M | $628.13M |
| Cost and Expenses | $5.15B | $4.53B | $4.92B | $5.06B | $4.75B | $5.09B | $4.31B | $4.86B | $4.47B | $4.36B | $3.74B | $4.20B | $3.93B | $3.70B | $3.58B | $3.58B | $3.46B | $3.24B | $3.04B | $3.48B |
| Interest Income | $- | $48.62M | $- | $138.99M | $153.86M | $68.79M | $66.56M | $- | $61.45M | $70.92M | $70.68M | $32.55M | $34.43M | $99.01M | $46.98M | $54.64M | $35.84M | $26.54M | $45.56M | $35.03M |
| Interest Expense | $- | $415.38M | $- | $985.69M | $604.51M | $321.55M | $169.57M | $297.68M | $289.73M | $274.89M | $242.69M | $223.77M | $227.50M | $124.50M | $159.10M | $323.63M | $149.74M | $129.65M | $148.94M | $302.43M |
| Depreciation and Amortization | $592.89M | $789.44M | $773.78M | $749.21M | $713.45M | $670.77M | $657.13M | $649.22M | $613.70M | $598.15M | $589.73M | $593.29M | $564.90M | $553.04M | $542.04M | $526.81M | $528.19M | $498.55M | $483.57M | $480.73M |
| EBITDA | $10.44B | $3.07B | $2.42B | $2.89B | $2.44B | $2.15B | $2.18B | $1.62B | $2.62B | $1.48B | $2.35B | $1.38B | $1.53B | $1.89B | $1.48B | $1.98B | $1.33B | $1.15B | $-295.64M | $1.49B |
| EBITDA Ratio | 69.63% | 45.47% | 36.87% | 40.69% | 38.20% | 23.84% | 34.39% | 18.90% | 40.07% | 29.80% | 23.11% | 26.33% | 33.00% | 30.12% | 33.58% | 35.63% | 32.11% | 36.64% | 35.34% | 36.64% |
| Operating Income | $9.85B | $2.22B | $1.65B | $2.21B | $1.75B | $1.06B | $1.30B | $472.20M | $1.79B | $908.19M | $535.63M | $5.86B | $-602.02M | $-633.27M | $-524.39M | $6.04B | $-509.79M | $-421.09M | $-617.31M | $7.21B |
| Operating Income Ratio | 65.68% | 32.91% | 25.08% | 30.38% | 27.14% | 17.24% | 22.86% | 7.96% | 29.82% | 17.25% | 11.00% | 115.67% | -11.68% | -13.78% | -11.21% | 123.68% | -11.49% | -9.50% | -15.27% | 153.58% |
| Total Other Income Expenses Net | $-515.74M | $-466.51M | $-329.30M | $-930.03M | $-441.11M | $-4.00M | $-260.35M | $98.39M | $-147.26M | $-318.45M | $329.27M | $-3.53B | $-537.48M | $234.41M | $-346.32M | $-3.36B | $-348.23M | $-583.98M | $-1.99B | $-4.51B |
| Income Before Tax | $9.33B | $1.75B | $1.31B | $1.28B | $1.28B | $1.06B | $1.13B | $570.60M | $1.64B | $589.74M | $1.47B | $565.03M | $706.48M | $1.15B | $750.62M | $1.13B | $655.56M | $517.09M | $-977.26M | $1.20B |
| Income Before Tax Ratio | 62.24% | 26.00% | 20.04% | 17.58% | 19.80% | 17.17% | 19.88% | 9.62% | 27.36% | 11.20% | 30.27% | 11.16% | 13.71% | 24.98% | 16.05% | 23.15% | 14.77% | 11.67% | -24.18% | 25.54% |
| Income Tax Expense | $3.22B | $545.20M | $500.56M | $100.28M | $431.35M | $313.09M | $385.73M | $-71.61M | $557.15M | $167.28M | $498.66M | $-2.40M | $237.95M | $374.98M | $253.76M | $299.08M | $233.98M | $138.93M | $-319.31M | $142.33M |
| Net Income | $6.11B | $1.21B | $823.29M | $1.19B | $846.29M | $743.74M | $747.21M | $642.21M | $1.08B | $422.46M | $975.54M | $567.43M | $468.53M | $773.05M | $496.86M | $831.53M | $421.58M | $378.16M | $-657.95M | $1.06B |
| Net Income Ratio | 40.75% | 17.92% | 12.55% | 16.33% | 13.11% | 12.08% | 13.11% | 10.83% | 18.05% | 8.02% | 20.03% | 11.21% | 9.09% | 16.82% | 10.62% | 17.02% | 9.50% | 8.53% | -16.28% | 22.51% |
| EPS | $8.94 | $1.77 | $1.20 | $1.74 | $1.24 | $1.09 | $1.09 | $0.94 | $1.58 | $0.62 | $1.43 | $0.83 | $0.69 | $1.13 | $0.73 | $1.22 | $0.62 | $0.55 | $-0.96 | $1.55 |
| EPS Diluted | $8.94 | $1.77 | $1.20 | $1.74 | $1.24 | $1.09 | $1.09 | $0.94 | $1.58 | $0.62 | $1.43 | $0.83 | $0.69 | $1.13 | $0.73 | $1.22 | $0.62 | $0.55 | $-0.96 | $1.55 |
| Weighted Average Shares Outstanding | 683.51M | 683.51M | 683.51M | 683.51M | 683.51M | 683.51M | 683.51M | 683.51M | 683.51M | 681.38M | 682.20M | 683.51M | 683.51M | 683.51M | 680.63M | 683.51M | 683.51M | 683.51M | 683.51M | 683.51M |
| Weighted Average Shares Outstanding Diluted | 683.51M | 683.51M | 683.51M | 683.51M | 683.51M | 683.51M | 683.51M | 683.51M | 683.51M | 681.38M | 682.20M | 683.51M | 683.51M | 684.12M | 680.63M | 683.51M | 683.51M | 683.51M | 683.51M | 683.51M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $838.48M | $1.87B | $717.93M | $396.40M | $2.25B |
| Short Term Investments | $2.43B | $1.68B | $2.43B | $3.41B | $- |
| Cash and Short Term Investments | $3.27B | $3.55B | $3.15B | $3.81B | $2.25B |
| Net Receivables | $3.70B | $3.51B | $3.14B | $2.39B | $2.23B |
| Inventory | $86.01M | $124.25M | $113.51M | $104.85M | $70.45M |
| Other Current Assets | $728.91M | $103.79M | $93.34M | $133.69M | $342.29M |
| Total Current Assets | $7.78B | $7.28B | $6.50B | $6.44B | $4.90B |
| Property Plant Equipment Net | $592.62M | $338.94M | $291.16M | $268.25M | $314.39M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $43.89B | $39.32B | $36.50B | $34.41B | $32.33B |
| Goodwill and Intangible Assets | $43.89B | $39.32B | $36.50B | $34.41B | $32.33B |
| Long Term Investments | $161.86M | $110.77M | $79.44M | $63.42M | $53.19M |
| Tax Assets | $98.08M | $- | $9.46B | $8.90B | $8.66B |
| Other Non-Current Assets | $8.94B | $10.15B | $323.70M | $339.57M | $210.45M |
| Total Non-Current Assets | $53.69B | $49.92B | $46.66B | $43.98B | $41.56B |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $61.47B | $57.21B | $53.17B | $50.42B | $46.46B |
| Account Payables | $456.21M | $430.95M | $236.76M | $263.74M | $369.63M |
| Short Term Debt | $2.62B | $2.25B | $1.83B | $3.03B | $2.86B |
| Tax Payables | $205.96M | $293.46M | $257.13M | $266.82M | $250.32M |
| Deferred Revenue | $21.97M | $131.07M | $2.51B | $2.12B | $2.67B |
| Other Current Liabilities | $5.11B | $3.69B | $2.77B | $2.34B | $2.97B |
| Total Current Liabilities | $8.41B | $6.66B | $5.09B | $5.90B | $6.45B |
| Long Term Debt | $16.92B | $16.71B | $15.89B | $14.22B | $10.38B |
| Deferred Revenue Non-Current | $12.05M | $12.20M | $3.12B | $3.51B | $3.99B |
| Deferred Tax Liabilities Non-Current | $164.10M | $189.28M | $283.74M | $320.72M | $434.00M |
| Other Non-Current Liabilities | $6.27B | $6.30B | $7.25B | $7.50B | $7.98B |
| Total Non-Current Liabilities | $23.21B | $23.22B | $23.14B | $21.72B | $18.37B |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $31.61B | $29.87B | $28.23B | $27.62B | $24.82B |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $15.00B | $15.00B | $15.00B | $15.00B | $15.00B |
| Retained Earnings | $14.71B | $76.93M | $9.89B | $8.19B | $7.55B |
| Accumulated Other Comprehensive Income Loss | $14.86B | $12.33B | $9.93B | $7.79B | $6.64B |
| Other Total Stockholders Equity | $-14.71B | $-76.93M | $-9.89B | $-8.19B | $-7.55B |
| Total Stockholders Equity | $29.86B | $27.33B | $24.93B | $22.79B | $21.64B |
| Total Equity | $29.86B | $27.33B | $24.93B | $22.79B | $21.64B |
| Total Liabilities and Stockholders Equity | $61.47B | $57.21B | $53.17B | $50.42B | $46.46B |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $61.47B | $57.21B | $53.17B | $50.42B | $46.46B |
| Total Investments | $2.59B | $1.79B | $2.51B | $3.47B | $53.19M |
| Total Debt | $19.54B | $18.96B | $17.72B | $17.26B | $13.24B |
| Net Debt | $18.70B | $17.09B | $17.01B | $16.86B | $10.99B |
Balance Sheet Charts
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $2.39B | $2.86B | $2.07B | $893.43M | $1.59B | $1.33B | $836.45M | $1.87B | $1.79B | $643.57M | $491.49M | $717.93M | $2.40B | $249.93M | $864.48M | $396.40M | $113.79M | $3.37B | $2.32B | $2.25B |
| Short Term Investments | $1.28B | $2.34B | $4.17B | $2.43B | $1.38B | $929.18M | $1.65B | $1.68B | $1.63B | $1.97B | $2.92B | $2.43B | $1.75B | $2.70B | $2.64B | $3.41B | $1.82B | $- | $- | $- |
| Cash and Short Term Investments | $3.67B | $5.15B | $6.24B | $3.32B | $2.97B | $2.26B | $2.49B | $3.55B | $3.42B | $2.61B | $3.41B | $3.15B | $4.15B | $2.95B | $3.51B | $3.81B | $1.93B | $3.37B | $2.32B | $2.25B |
| Net Receivables | $3.76B | $3.79B | $4.19B | $4.34B | $3.89B | $3.77B | $3.66B | $3.51B | $3.49B | $3.36B | $3.34B | $3.14B | $2.70B | $2.46B | $2.49B | $2.39B | $2.46B | $2.50B | $2.16B | $2.23B |
| Inventory | $98.12M | $116.09M | $122.17M | $86.01M | $120.61M | $120.61M | $117.30M | $124.25M | $120.06M | $122.88M | $117.51M | $113.51M | $105.97M | $108.87M | $105.93M | $104.85M | $97.33M | $84.75M | $67.90M | $70.45M |
| Other Current Assets | $641.36M | $713.26M | $120.28M | $91.99M | $134.67M | $119.91M | $141.47M | $103.79M | $111.87M | $120.15M | $131.49M | $93.34M | $110.27M | $144.71M | $176.29M | $133.69M | $31.17M | $28.59M | $607.05M | $342.29M |
| Total Current Assets | $8.17B | $9.77B | $10.62B | $7.78B | $7.12B | $6.26B | $6.40B | $7.28B | $7.14B | $6.21B | $7.00B | $6.50B | $7.06B | $5.66B | $6.28B | $6.44B | $4.52B | $5.98B | $5.16B | $4.90B |
| Property Plant Equipment Net | $659.88M | $498.44M | $484.31M | $474.56M | $418.42M | $371.21M | $364.87M | $338.94M | $302.25M | $297.23M | $289.23M | $291.16M | $276.97M | $267.47M | $269.47M | $268.25M | $259.62M | $318.59M | $316.45M | $314.39M |
| Goodwill | $143.90M | $159.16M | $226.69M | $- | $-10.88M | $- | $58.08M | $- | $- | $84.65M | $94.89M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $41.68B | $44.62B | $44.23B | $43.89B | $41.84B | $40.40B | $39.69B | $39.32B | $38.08B | $36.98B | $36.82B | $36.50B | $35.59B | $35.59B | $34.70B | $34.41B | $33.54B | $33.34B | $32.18B | $32.33B |
| Goodwill and Intangible Assets | $41.82B | $44.78B | $44.46B | $43.89B | $41.83B | $40.40B | $39.74B | $39.32B | $38.08B | $37.07B | $36.91B | $36.50B | $35.59B | $35.59B | $34.70B | $34.41B | $33.54B | $33.34B | $32.18B | $32.33B |
| Long Term Investments | $17.22B | $9.36B | $9.20B | $8.94B | $156.37M | $154.91M | $149.55M | $110.77M | $92.93M | $86.99M | $85.02M | $79.44M | $79.24M | $75.63M | $71.47M | $63.42M | $63.17M | $59.67M | $56.33M | $53.19M |
| Tax Assets | $-143.90M | $1.46B | $1.42B | $1.41B | $9.09B | $10.07B | $- | $- | $- | $- | $- | $9.46B | $9.74B | $9.00B | $9.25B | $9.05B | $9.20B | $8.83B | $8.92B | $8.66B |
| Other Non-Current Assets | $8.26B | $142.50M | $164.56M | $279.75M | $369.52M | $200.67M | $10.26B | $10.15B | $10.38B | $10.29B | $9.81B | $323.70M | $331.99M | $323.38M | $335.43M | $191.41M | $196.94M | $209.48M | $340.62M | $210.45M |
| Total Non-Current Assets | $67.97B | $56.24B | $55.73B | $55.00B | $51.86B | $51.19B | $50.52B | $49.92B | $48.86B | $47.74B | $47.09B | $46.66B | $46.01B | $45.26B | $44.63B | $43.98B | $43.26B | $42.76B | $41.81B | $41.56B |
| Other Assets | $- | $-1.33B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $76.13B | $64.68B | $66.35B | $62.78B | $58.98B | $57.45B | $56.93B | $57.21B | $55.99B | $53.95B | $54.09B | $53.17B | $53.08B | $50.92B | $50.91B | $50.42B | $47.79B | $48.74B | $46.97B | $46.46B |
| Account Payables | $268.92M | $497.82M | $490.49M | $456.21M | $518.20M | $256.68M | $257.75M | $430.95M | $289.13M | $311.74M | $252.05M | $236.76M | $257.19M | $225.90M | $250.02M | $263.74M | $237.84M | $396.95M | $242.11M | $369.63M |
| Short Term Debt | $2.64B | $2.42B | $2.69B | $2.62B | $2.65B | $2.58B | $1.98B | $2.25B | $1.79B | $2.32B | $2.30B | $1.83B | $3.28B | $3.28B | $3.23B | $3.03B | $1.46B | $3.42B | $3.28B | $2.86B |
| Tax Payables | $271.11M | $164.05M | $389.71M | $205.96M | $310.16M | $232.70M | $338.25M | $293.46M | $283.34M | $201.56M | $383.06M | $257.13M | $262.24M | $258.07M | $255.02M | $266.82M | $428.18M | $41.91M | $172.60M | $250.32M |
| Deferred Revenue | $35.00K | $19.52M | $20.90M | $21.97M | $2.99B | $2.74B | $92.86M | $131.07M | $130.40M | $130.84M | $135.57M | $2.51B | $2.07B | $1.90B | $2.20B | $2.12B | $2.02B | $2.25B | $2.86B | $2.67B |
| Other Current Liabilities | $4.00B | $4.07B | $5.06B | $5.11B | $3.55B | $3.38B | $3.59B | $3.69B | $2.48B | $1.95B | $2.28B | $2.77B | $2.34B | $2.17B | $2.47B | $2.34B | $2.09B | $2.83B | $3.25B | $2.97B |
| Total Current Liabilities | $7.17B | $7.17B | $8.66B | $8.41B | $7.06B | $6.45B | $6.16B | $6.66B | $4.84B | $4.78B | $5.21B | $5.09B | $6.14B | $5.93B | $6.20B | $5.90B | $4.22B | $6.68B | $6.95B | $6.45B |
| Long Term Debt | $21.22B | $19.36B | $20.62B | $16.92B | $16.35B | $16.13B | $16.32B | $16.71B | $16.99B | $15.94B | $15.85B | $15.89B | $14.64B | $13.21B | $13.79B | $14.22B | $13.92B | $12.97B | $11.27B | $10.38B |
| Deferred Revenue Non-Current | $- | $12.31M | $12.14M | $12.05M | $2.83B | $2.95B | $12.32M | $12.20M | $12.00M | $12.76M | $12.30M | $3.12B | $3.54B | $3.53B | $3.51B | $3.51B | $3.98B | $3.89B | $3.89B | $3.99B |
| Deferred Tax Liabilities Non-Current | $3.65B | $176.35M | $1.48B | $1.48B | $232.06M | $101.91M | $191.52M | $189.28M | $365.51M | $280.00M | $292.90M | $283.74M | $295.39M | $319.02M | $326.61M | $320.72M | $452.23M | $409.68M | $376.41M | $434.00M |
| Other Non-Current Liabilities | $6.18B | $7.50B | $7.88B | $6.11B | $2.92B | $6.13B | $6.16B | $6.30B | $6.46B | $6.67B | $6.82B | $7.25B | $7.80B | $7.74B | $7.62B | $7.50B | $7.95B | $7.81B | $7.77B | $7.98B |
| Total Non-Current Liabilities | $31.05B | $27.05B | $27.02B | $24.52B | $22.33B | $22.26B | $22.68B | $23.22B | $23.80B | $22.90B | $22.97B | $23.14B | $22.43B | $20.95B | $21.41B | $21.72B | $21.87B | $20.78B | $19.04B | $18.37B |
| Other Liabilities | $- | $-1.33B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $38.23B | $32.88B | $35.67B | $32.93B | $29.39B | $28.71B | $28.85B | $29.87B | $28.64B | $27.68B | $28.19B | $28.23B | $28.57B | $26.88B | $27.62B | $27.62B | $26.09B | $27.46B | $25.99B | $24.82B |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1 | $- | $- |
| Common Stock | $15.00B | $15.00B | $15.00B | $15.00B | $15.00B | $15.00B | $15.00B | $15.00B | $15.00B | $15.00B | $15.00B | $15.00B | $15.00B | $15.00B | $15.00B | $15.00B | $15.00B | $15.00B | $15.00B | $15.00B |
| Retained Earnings | $8.14B | $2.03B | $823.29M | $14.71B | $2.34B | $1.49B | $747.21M | $76.93M | $2.48B | $1.40B | $975.54M | $9.89B | $1.74B | $1.27B | $523.23M | $8.19B | $141.79M | $-279.79M | $-576.97M | $7.55B |
| Accumulated Other Comprehensive Income Loss | $14.76B | $14.76B | $14.86B | $14.86B | $12.26B | $12.26B | $12.33B | $12.33B | $9.83B | $9.88B | $9.93B | $9.93B | $8.17B | $8.17B | $8.17B | $7.79B | $6.55B | $6.55B | $7.47B | $6.64B |
| Other Total Stockholders Equity | $- | $- | $- | $-14.71B | $- | $- | $- | $-76.93M | $- | $- | $- | $-9.89B | $-401.00M | $-401.00M | $-401.00M | $-8.19B | $- | $- | $- | $-7.55B |
| Total Stockholders Equity | $37.91B | $31.80B | $30.68B | $29.86B | $29.59B | $28.75B | $28.08B | $27.33B | $27.36B | $26.27B | $25.91B | $24.93B | $24.51B | $24.04B | $23.29B | $22.79B | $21.70B | $21.28B | $20.98B | $21.64B |
| Total Equity | $37.91B | $31.80B | $30.68B | $29.86B | $29.59B | $28.75B | $28.08B | $27.33B | $27.36B | $26.27B | $25.91B | $24.93B | $24.51B | $24.04B | $23.29B | $22.79B | $21.70B | $21.28B | $20.98B | $21.64B |
| Total Liabilities and Stockholders Equity | $76.13B | $66.01B | $66.35B | $62.78B | $58.98B | $57.45B | $56.93B | $57.21B | $55.99B | $53.95B | $54.09B | $53.17B | $53.08B | $50.92B | $50.91B | $50.42B | $47.79B | $48.74B | $46.97B | $46.46B |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $76.13B | $66.01B | $66.35B | $62.78B | $58.98B | $57.45B | $56.93B | $57.21B | $55.99B | $53.95B | $54.09B | $53.17B | $53.08B | $50.92B | $50.91B | $50.42B | $47.79B | $48.74B | $46.97B | $46.46B |
| Total Investments | $18.50B | $11.70B | $13.38B | $11.37B | $1.54B | $1.08B | $1.80B | $1.79B | $1.72B | $2.05B | $3.00B | $2.51B | $1.82B | $2.77B | $2.72B | $3.47B | $1.88B | $59.67M | $56.33M | $53.19M |
| Total Debt | $23.86B | $21.78B | $22.00B | $19.51B | $19.00B | $18.71B | $18.30B | $18.96B | $18.78B | $17.73B | $17.63B | $17.72B | $17.92B | $16.49B | $17.02B | $17.26B | $15.38B | $16.39B | $14.55B | $13.24B |
| Net Debt | $21.46B | $18.97B | $19.94B | $18.62B | $17.41B | $17.38B | $17.46B | $17.09B | $16.99B | $17.08B | $17.14B | $17.01B | $15.52B | $16.24B | $16.15B | $16.86B | $15.27B | $13.02B | $12.23B | $10.99B |
Annual Cash Flow
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Net Income | $3.52B | $4.27B | $3.17B | $1.33B | $4.68B |
| Depreciation and Amortization | $2.79B | $2.45B | $2.25B | $2.04B | $1.78B |
| Deferred Income Tax | $- | $- | $- | $- | $- |
| Stock Based Compensation | $- | $- | $- | $- | $- |
| Change in Working Capital | $-2.66B | $-2.11B | $-1.52B | $-1.08B | $-620.02M |
| Accounts Receivables | $-1.09B | $-784.98M | $-721.60M | $-129.66M | $-46.18M |
| Inventory | $38.24M | $-10.74M | $-8.66M | $-34.39M | $-4.86M |
| Accounts Payables | $-394.19M | $-220.46M | $-245.50M | $-248.40M | $-349.04M |
| Other Working Capital | $-1.22B | $-1.09B | $-544.67M | $-663.83M | $-219.95M |
| Other Non Cash Items | $1.20B | $-647.26M | $10.70M | $2.69B | $-1.64B |
| Net Cash Provided by Operating Activities | $4.85B | $3.97B | $3.91B | $4.98B | $4.20B |
| Investments in Property Plant and Equipment | $-147.25M | $-73.67M | $-50.28M | $-42.41M | $-78.16M |
| Acquisitions Net | $- | $9.65M | $- | $- | $- |
| Purchases of Investments | $- | $-9.65M | $- | $-3.42B | $- |
| Sales Maturities of Investments | $- | $755.51M | $1.08B | $- | $240.00K |
| Other Investing Activities | $-4.76B | $-3.56B | $-3.69B | $-3.31B | $-3.19B |
| Net Cash Used for Investing Activities | $-4.91B | $-2.88B | $-2.66B | $-6.77B | $-3.27B |
| Debt Repayment | $600.02M | $1.27B | $26.21M | $1.53B | $-354.81M |
| Common Stock Issued | $811.00K | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $-823.67M | $-603.54M | $-254.22M | $-890.10M | $-740.00M |
| Other Financing Activities | $-755.00M | $-606.46M | $-701.01M | $-709.63M | $-611.14M |
| Net Cash Used Provided by Financing Activities | $-977.84M | $60.30M | $-929.02M | $-66.35M | $-1.71B |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $-1.03B | $1.15B | $321.53M | $-1.86B | $-775.98M |
| Cash at End of Period | $838.48M | $1.87B | $717.93M | $396.40M | $2.25B |
| Cash at Beginning of Period | $1.87B | $717.93M | $396.40M | $2.25B | $3.03B |
| Operating Cash Flow | $4.85B | $3.97B | $3.91B | $4.98B | $4.20B |
| Capital Expenditure | $-147.25M | $-73.67M | $-50.28M | $-42.41M | $-78.16M |
| Free Cash Flow | $4.71B | $3.89B | $3.86B | $4.94B | $4.12B |
Cash Flow Charts
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $9.33B | $1.21B | $823.29M | $1.19B | $1.28B | $1.06B | $1.13B | $570.60M | $1.64B | $589.74M | $1.47B | $565.03M | $706.48M | $1.15B | $750.62M | $1.13B | $655.56M | $517.09M | $-977.26M | $1.20B |
| Depreciation and Amortization | $592.89M | $789.44M | $773.78M | $749.21M | $713.46M | $670.77M | $657.14M | $649.23M | $613.71M | $598.16M | $589.75M | $593.30M | $564.91M | $553.05M | $542.05M | $526.81M | $528.19M | $498.55M | $483.57M | $480.73M |
| Deferred Income Tax | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Change in Working Capital | $439.85M | $-278.93M | $-631.60M | $-343.25M | $-335.52M | $-720.48M | $-1.46B | $-170.24M | $-583.96M | $-456.81M | $-897.73M | $-1.52B | $658.91M | $-412.24M | $-246.67M | $-446.87M | $-685.71M | $450.77M | $-394.49M | $-269.00M |
| Accounts Receivables | $912.61M | $11.48M | $11.84M | $-503.31M | $-147.60M | $-219.47M | $-173.51M | $-577.45M | $-351.38M | $-133.59M | $-309.83M | $-309.44M | $-244.97M | $-63.52M | $-103.67M | $-90.05M | $-353.85M | $228.47M | $85.76M | $-15.14M |
| Inventory | $17.97M | $6.08M | $-36.16M | $34.60M | $6.00K | $-3.32M | $6.95M | $-4.19M | $2.82M | $-5.37M | $-4.00M | $-7.53M | $2.89M | $-2.93M | $-1.09M | $-7.52M | $-12.59M | $-16.85M | $2.56M | $24.73M |
| Accounts Payables | $-8.64M | $-9.89M | $-419.39M | $15.46M | $2.33M | $2.05M | $-414.03M | $3.58M | $-291.00K | $-5.16M | $-218.60M | $-3.17M | $-91.00K | $-99.27M | $-142.98M | $-4.05M | $-74.81M | $69.73M | $-239.27M | $2.05M |
| Other Working Capital | $-482.08M | $-286.60M | $-187.90M | $110.01M | $-190.26M | $-499.75M | $-880.41M | $407.81M | $-235.12M | $-312.70M | $-365.29M | $-1.20B | $901.08M | $-246.53M | $1.06M | $-345.25M | $-244.46M | $169.42M | $-243.53M | $-280.64M |
| Other Non Cash Items | $-8.80B | $52.65M | $2.42B | $2.07B | $-171.54M | $110.60M | $66.22M | $348.85M | $-862.66M | $415.94M | $-549.38M | $1.03B | $-655.48M | $-360.33M | $-1.49M | $-120.06M | $515.41M | $219.32M | $2.08B | $-239.39M |
| Net Cash Provided by Operating Activities | $1.57B | $1.77B | $1.40B | $1.71B | $1.48B | $1.12B | $395.31M | $1.40B | $805.30M | $1.15B | $616.84M | $665.90M | $1.27B | $928.52M | $1.04B | $1.09B | $1.01B | $1.69B | $1.19B | $1.17B |
| Investments in Property Plant and Equipment | $-26.23M | $-1.15B | $-587.32M | $-1.69B | $-47.96M | $-9.33M | $-30.95M | $-33.20M | $-17.67M | $-14.23M | $-8.57M | $-22.91M | $-14.49M | $-4.54M | $-659.25M | $-16.62M | $-5.12M | $-11.08M | $-403.16M | $-21.97M |
| Acquisitions Net | $- | $- | $- | $- | $492.46M | $-804.39M | $-17.73M | $461.00K | $-384.38M | $-882.21M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $-1.71B | $-765.26M | $5.03M | $4.12M | $-10.83M | $-461.00K | $-6.07M | $440.59M | $-443.71M | $- | $- | $349.00K | $-349.00K | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $9.25M | $-331.34M | $-497.49M | $800.27M | $28.56M | $-77.81M | $390.45M | $441.62M | $1.26M | $-607.68M | $953.24M | $-50.64M | $781.54M | $- | $- | $- | $- | $- |
| Other Investing Activities | $-3.88B | $1.83B | $-562.16M | $16.26M | $-1.21B | $-130.93M | $-552.60M | $-1.04B | $-628.62M | $39.23M | $-1.09B | $-1.22B | $-1.00B | $-813.66M | $-349.00K | $-2.56B | $-2.90B | $-864.04M | $-345.00K | $-1.17B |
| Net Cash Used for Investing Activities | $-3.91B | $676.41M | $-2.28B | $-2.77B | $-1.26B | $-140.26M | $-583.55M | $-1.15B | $-646.29M | $25.00M | $-1.10B | $-1.85B | $-64.64M | $-868.84M | $121.94M | $-2.58B | $-2.91B | $-875.12M | $-403.50M | $-1.19B |
| Debt Repayment | $2.08B | $-593.92M | $2.28B | $484.40M | $1.02B | $509.74M | $-594.63M | $-50.97M | $1.15B | $-249.87M | $423.24M | $-294.75M | $1.09B | $-263.04M | $-510.84M | $1.94B | $1.03B | $1.30B | $-550.44M | $-208.12M |
| Common Stock Issued | $- | $- | $- | $- | $811.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $-823.67M | $-823.67M | $- | $- | $- | $-603.54M | $- | $- | $- | $-254.22M | $- | $- | $-44.00K | $-890.05M | $- | $-6.00K |
| Other Financing Activities | $-163.15M | $-1.07B | $-211.37M | $-175.71M | $-981.18M | $-172.81M | $-248.16M | $-114.36M | $-161.72M | $-166.54M | $-163.84M | $-203.59M | $-152.92M | $-156.96M | $-187.53M | $-164.07M | $-2.39B | $-178.19M | $-164.43M | $-152.20M |
| Net Cash Used Provided by Financing Activities | $1.92B | $-1.66B | $2.07B | $308.69M | $43.00M | $-486.74M | $-842.79M | $-165.33M | $986.18M | $-1.02B | $259.40M | $-498.34M | $941.91M | $-674.23M | $-698.37M | $1.77B | $-1.36B | $232.43M | $-714.87M | $-360.32M |
| Effect of Forex Changes on Cash | $- | $- | $- | $1.21M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-1.93B | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-416.13M | $794.99M | $1.17B | $-754.01M | $265.71M | $490.72M | $-1.03B | $78.73M | $1.15B | $152.08M | $-226.44M | $-1.68B | $2.15B | $-2.54B | $468.08M | $282.62M | $-3.25B | $1.04B | $70.16M | $-380.20M |
| Cash at End of Period | $2.39B | $2.86B | $2.07B | $893.43M | $1.59B | $1.33B | $836.45M | $1.87B | $1.79B | $643.57M | $491.49M | $717.93M | $2.40B | $249.93M | $2.79B | $396.40M | $113.79M | $3.37B | $2.32B | $2.25B |
| Cash at Beginning of Period | $2.81B | $2.07B | $893.43M | $1.65B | $1.33B | $836.45M | $1.87B | $1.79B | $643.57M | $491.49M | $717.93M | $2.40B | $249.93M | $2.79B | $2.32B | $113.79M | $3.37B | $2.32B | $2.25B | $2.63B |
| Operating Cash Flow | $1.57B | $1.77B | $1.40B | $1.71B | $1.48B | $1.12B | $395.31M | $1.40B | $805.30M | $1.15B | $616.84M | $665.90M | $1.27B | $928.52M | $1.04B | $1.09B | $1.01B | $1.69B | $1.19B | $1.17B |
| Capital Expenditure | $-26.23M | $-20.60M | $-587.32M | $-1.69B | $-47.96M | $-9.33M | $-30.95M | $-33.20M | $-17.67M | $-14.23M | $-8.57M | $-22.91M | $-14.49M | $-4.54M | $-659.25M | $-16.62M | $-5.12M | $-11.08M | $-403.16M | $-21.97M |
| Free Cash Flow | $1.54B | $1.75B | $810.10M | $16.44M | $1.44B | $1.11B | $364.35M | $1.37B | $787.62M | $1.13B | $608.28M | $642.99M | $1.26B | $923.98M | $385.26M | $1.07B | $1.01B | $1.67B | $785.37M | $1.15B |
Companhia de Saneamento Básico do Estado de São Paulo - SABESP Dividends
Explore Companhia de Saneamento Básico do Estado de São Paulo - SABESP's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
1.67%
Dividend Payout Ratio
23.38%
Dividend Paid & Capex Coverage Ratio
5.00x
Companhia de Saneamento Básico do Estado de São Paulo - SABESP Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $0.21288 | $0.21288 | April 26, 2024 | April 29, 2024 | July 05, 2024 | |
| $0.2527 | $0.2527 | May 02, 2023 | May 03, 2023 | July 06, 2023 | April 21, 2023 |
| $0.188 | $0.188 | April 29, 2022 | May 02, 2022 | July 07, 2022 | April 06, 2022 |
| $0.0801 | $0.071373 | April 30, 2021 | May 03, 2021 | July 08, 2021 | April 07, 2021 |
| $0.252 | $0.2518 | May 01, 2020 | May 04, 2020 | June 08, 2020 | April 23, 2020 |
| $0.3 | $0.2999 | April 30, 2019 | May 01, 2019 | July 08, 2019 | April 15, 2019 |
| $0.311 | $0.311 | April 30, 2018 | May 01, 2018 | July 06, 2018 | April 03, 2018 |
| $0.384 | $0.3843 | April 11, 2017 | April 13, 2017 | July 07, 2017 | March 28, 2017 |
| $0.06 | $0.06 | April 06, 2016 | April 08, 2016 | July 08, 2016 | March 29, 2016 |
| $0.114 | $0.114 | April 07, 2015 | July 09, 2015 | ||
| $0.306 | $0.306 | April 08, 2014 | July 07, 2014 | ||
| $1.163 | $0.38767 | April 01, 2013 | April 03, 2013 | July 01, 2013 | |
| $2.959 | $0.49317 | February 17, 2012 | |||
| $4.772 | $0.79533 | December 28, 2010 | |||
| $0.162 | $0.027 | March 01, 2010 | July 08, 2010 | ||
| $1.135 | $0.18917 | November 23, 2009 | |||
| $0.576 | $0.096 | May 29, 2009 | |||
| $0.357 | $0.0595 | January 27, 2009 | |||
| $1.117 | $0.18617 | August 13, 2008 | |||
| $0.164 | $0.027333 | February 28, 2008 |
Companhia de Saneamento Básico do Estado de São Paulo - SABESP News
Read the latest news about Companhia de Saneamento Básico do Estado de São Paulo - SABESP, including recent articles, headlines, and updates.
Jaguar Receives Regulatory Clearance in Germany and Italy for Crofelemer for Rare Disease Study - Short Bowel Syndrome with Intestinal Failure (SBS-IF)
This study, initiated yesterday, is one of five clinical efforts - three proof-of-concept (POC) investigator-initiated trials (IIT) and two Phase 2 studies - of crofelemer for the rare disease indications of SBS-IF and microvillus inclusion disease (MVID) in the US, EU, and/or Middle East/North Africa regions Availability of first IIT proof-of-concept results potentially in H1 2025 Crofelemer, Jaguar's novel plant-based prescription drug, has been granted Orphan-Drug Designation by the FDA and the European Medicines Agency (EMA) for both SBS-IF and MVID SAN FRANCISCO, CA / ACCESS Newswire / February 19, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") family companies Napo Pharmaceuticals ("Napo") and Napo Therapeutics today announced that the clinical protocol for Napo's Phase 2 study to evaluate the efficacy of crofelemer, Jaguar's novel plant-based anti-secretory prescription drug, for the indication of SBS-IF in adults has received regulatory clearance from health authorities in Italy and Germany, where the trial will be conducted. The study initiated yesterday, February 18, 2025.
Is Companhia de saneamento Basico Do Estado De Sao Paulo Sabesp (SBS) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
U.S. Investigator-Initiated Trial (IIT) to Evaluate Jaguar Health's Crofelemer for Short Bowel Syndrome with Intestinal Failure (SBS-IF) Begins
The study is one of five clinical efforts - three IIT proof-of-concept studies and two Phase 2 studies - of crofelemer for the rare disease indications of SBS-IF and/or microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder, in the US, EU, and/or Middle East/North Africa (MENA) regions; availability of IIT proof-of-concept results potentially in Q2 2025 Crofelemer, Jaguar's novel plant-based prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both SBS-IF and MVID SAN FRANCISCO, CA / ACCESSWIRE / December 6, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that an independent IIT in the U.S. to evaluate the efficacy and safety of crofelemer, Jaguar's novel plant-based anti-diarrheal prescription drug, for the rare disease indication of short bowel syndrome with intestinal failure (SBS-IF) in adults has begun. An overview of the study can be viewed on the ClinicalTrials.gov website.
Sabesp Q3: Good Result, But Macro Scenario Continues To Leave Me Skeptical
Recommend holding Sabesp shares post-3Q24 results due to good trends, but valuation lacks safety margin amid Brazilian economic instability. Net revenues rose 9.6% y/y to $987 million, driven by tariff adjustments and privatization impacts on corporate accounting. Operating costs fell 3.1% y/y, with a strong EBITDA margin of 59.9%, and net income increased 43.7% y/y to $201 million.
Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS) Q3 2024 Earnings Call Transcript
Companhia de Saneamento Básico do Estado de São Paulo - SABESP (NYSE:SBS ) Q3 2024 Earnings Conference Call November 12, 2024 9:00 AM ET Company Participants Luiz Tiberio - IR Superintendent Carlos Piani - CEO Daniel Szlak - Financial Director, Investor Relations Conference Call Participants Luiz Tiberio Good morning, everyone. My name is Luiz Roberto Tiberio.
Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, will present new findings at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting and Postgraduate Course from subgroup analyses of the primary endpoint of the pivotal Phase III clinical trial, STARS, evaluating the treatment effect of apraglutide by baseline demographics and disease-specific characteristics in adults with short bowel syndrome with intestinal failure.
Sabesp (SBS) Is a Great Choice for 'Trend' Investors, Here's Why
Sabesp (SBS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Patent Issued in Jordan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
New patent issued for core rare disease target indication for crofelemer Napo has approximately 230 patents issued and pending Jaguar is supporting independent investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder (CDD), in the US, EU, and Middle East/North Africa regions, with results expected by the end of 2024 and throughout 2025 SAN FRANCISCO, CA / ACCESSWIRE / August 27, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that the country of Jordan's Industrial Property Protection Directorate has issued a new patent to Jaguar family company Napo Pharmaceuticals (Napo) for methods for treating short bowel syndrome (SBS), bile acid diarrhea, and diarrhea associated with small intestine resection or gallbladder removal, in patients with an inhibitor of chloride-ion transport such as crofelemer, Jaguar's novel plant-based prescription drug. "We are very pleased that this patent has been issued and believe that it further enhances our intellectual property protection for crofelemer for our core rare disease target indication of SBS," said Lisa Conte, Jaguar's founder, president, and CEO.
Issuance of New Hong Kong Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
New patent issued for core rare disease target indication for crofelemer Napo has approximately 230 patents issued and pending Jaguar is supporting independent investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder (CDD), in the US, EU, and Middle East/North Africa regions, with results expected by the end of 2024 and throughout 2025 SAN FRANCISCO, CA / ACCESSWIRE / August 19, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Hong Kong's Intellectual Property Department has issued a new patent to Jaguar family company Napo Pharmaceuticals for methods for treating short bowel syndrome (SBS), bile acid diarrhea, and diarrhea associated with small intestine resection or gallbladder removal, in patients with an inhibitor of chloride-ion transport such as crofelemer, Jaguar's novel plant-based prescription drug. "We are very happy that this patent has been issued and believe that it further enhances our intellectual property protection for crofelemer for our core rare disease target indication of SBS," said Lisa Conte, Jaguar's founder, president, and CEO.
Here's Why Sabesp (SBS) is Poised for a Turnaround After Losing -11.66% in 4 Weeks
Sabesp (SBS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
SBS or GWRS: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Utility - Water Supply sector have probably already heard of Sabesp (SBS) and Global Water Resources, Inc. (GWRS). But which of these two stocks presents investors with the better value opportunity right now?
Should Value Investors Buy Companhia de saneamento Basico Do Estado De Sao Paulo Sabesp (SBS) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, will present late-breaking data during the 2024 Digestive Disease Week® (DDW) meeting from its pivotal Phase III clinical trial, STARS, which evaluated the efficacy and safety of once-weekly subcutaneous apraglutide in adult patients with short bowel syndrome with intestinal failure (SBS-IF). These findings build on the positive topline data that Ironwood previously announced in February 202.
Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS) Q1 2024 Earnings Call Transcript
Companhia de Saneamento Básico do Estado de São Paulo - SABESP (NYSE:SBS ) Q1 2024 Earnings Conference Call May 10, 2024 10:00 AM ET Company Participants Luiz Roberto Tiberio - IR Superintendent André Salcedo - CEO Catia Pereira - CFO and IR Officer Conference Call Participants Luiz Roberto Tiberio Hello. Good morning, everyone, and welcome to our earnings call for Q1 2024.
What Makes Companhia de saneamento Basico Do Estado De Sao Paulo Sabesp (SBS) a Good Fit for 'Trend Investing'
If you are looking for stocks that are well positioned to maintain their recent uptrend, Companhia de saneamento Basico Do Estado De Sao Paulo Sabesp (SBS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
SBS vs. GWRS: Which Stock Is the Better Value Option?
Investors interested in stocks from the Utility - Water Supply sector have probably already heard of Sabesp (SBS) and Global Water Resources, Inc. (GWRS). But which of these two stocks offers value investors a better bang for their buck right now?
Here's Why 'Trend' Investors Would Love Betting on Sabesp (SBS)
Sabesp (SBS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Sabesp: Privatization Just Around The Corner, Q3 Results Still Provide Room For Upside
Privatization of Brazilian water management company Sabesp is progressing, with a likely completion by the first half of 2024. The regulatory terms of the privatization will determine the company's long-term efficiency and potential for growth. The optimistic scenario envisions efficiency gains and a potential EV/RAB increase to 1.5x, suggesting a substantial upside.
Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS) Q3 2023 Earnings Call Transcript
Companhia de Saneamento Básico do Estado de São Paulo - SABESP (NYSE:SBS ) Q3 2023 Earnings Conference Call November 10, 2023 9:00 AM ET Company Participants Luiz Roberto Tiberio - Superintendent of IR Andre Salcedo - CEO Catia Pereira - CFO and IRO Conference Call Participants Luiz Roberto Tiberio Good morning, everyone. Welcome to the Earnings Conference Call for SABESP for the Third Quarter.
Sabesp: Privatization Gains Momentum, Stock Is A Buy (Rating Upgrade)
Sabesp's significant steps toward privatization, including the approval of privatization guidelines and a follow-on model, have boosted confidence in the company's prospects. In Q2, Sabesp reported robust financial results, with recurring EBITDA increasing significantly year-over-year. Sabesp's current valuation, with the potential for reduced cost of capital and improved long-term operating performance as a private sector company, suggests significant upside potential.
Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS) Q2 2023 Earnings Call Transcript
Companhia de Saneamento Básico do Estado de São Paulo - SABESP (NYSE:SBS ) Q2 2023 Earnings Conference Call August 11, 2023 10:00 AM ET Company Participants Luiz Roberto Tiberio - Superintendent of Investor Relations Andre Salcedo - Chief Executive Officer Catia Pereira - Chief Financial Officer and Investor Relations Officer Luiz Roberto Tiberio Good morning. Welcome to the SABESP Second Quarter Earnings Release Call.
Sabesp Stock: Evaluating Privatization's Impact, Neutral Stance
The potential privatization of the Brazilian water and waste management company, Sabesp, has impacted its shares, presenting an opportunity to enhance the company's efficiency. Sabesp's recent earnings results were satisfactory, showcasing a 17% year-over-year increase in net operating revenues despite recent volatility and a drop in net income, albeit with minor setbacks. While the company currently trades at an undervalued price, I adopt a cautious approach due to the risks associated with the changes of "Basic Sanitation Legal Framework" in Brazil.
Survey & Ballot Systems Launches Text Message Invites for Increased Voter Engagement
SBS launches verified text message invites to help member organizations increase voter participation within director elections, bylaw votes, mergers and contract ratification votes. EDEN PRAIRIE, Minn., March 16, 2023 /PRNewswire-PRWeb/ — Survey & Ballot Systems (SBS), a leading provider of online voting and governance software solutions, is excited to announce the launch of its newest […]...
Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS) Q3 2022 - Earnings Call Transcript
Companhia de Saneamento Básico do Estado de São Paulo - SABESP. (NYSE:SBS ) Q3 2022 Earnings Conference Call November 17, 2022 9:00 AM ET Company Participants Luiz Tiberio - Resource Funding and IRO Officer Benedito Braga - Chief Executive Officer of SABESP Osvaldo Garcia - Chief Financial Officer and Investor Relations Officer Marcelo Miyagui - Superintendent for Accounting Conference Call Participants Carolina Carneiro - Credit Suisse Henrique Peretti - JPMorgan Operator Good morning, everyone.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for SBS.